Supplementary Fig. S1 from Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer
Masayoshi Miyawaki(Keio University), Kenzo Soejima(Keio University), Shigenari Nukaga(Tokyo Medical Center), Tetsuo Tani(Keio University), Keiko Ohgino(Keio University), Kota Ishioka(Keio University), Tomoko Betsuyaku(Tokyo Medical University), Daisuke Arai(Keio University), Junko Hamamoto(Keio University), Hiroyuki Yasuda, Ichiro Kawada(Keio University), Katsuhiko Naoki(Broad Institute), Toshiyuki Hirano(Sapporo Kosei General Hospital)
Cited by 0
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
|Science Translational Medicine|2013|565
Activating Mutations of the Noonan Syndrome-Associated <b> <i>SHP2/PTPN11</i> </b> Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia
|Cancer Research|2004|512
<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancer
|Oncotarget|2015|159
MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer
|Cancer Cell|2022|101